Neuroblastoma Drugs Market - Global Outlook and Forecast 2023-2028

Report ID: 1370149 | Published Date: Jan 2025 | No. of Page: 62 | Base Year: 2024 | Rating: 4.9 | Webstory: Check our Web story
1 Introduction to Research & Analysis Reports
    1.1 Neuroblastoma Drugs Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Neuroblastoma Drugs Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Neuroblastoma Drugs Overall Market Size
    2.1 Global Neuroblastoma Drugs Market Size: 2021 VS 2028
    2.2 Global Neuroblastoma Drugs Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Neuroblastoma Drugs Players in Global Market
    3.2 Top Global Neuroblastoma Drugs Companies Ranked by Revenue
    3.3 Global Neuroblastoma Drugs Revenue by Companies
    3.4 Top 3 and Top 5 Neuroblastoma Drugs Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Neuroblastoma Drugs Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Neuroblastoma Drugs Players in Global Market
        3.6.1 List of Global Tier 1 Neuroblastoma Drugs Companies
        3.6.2 List of Global Tier 2 and Tier 3 Neuroblastoma Drugs Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Neuroblastoma Drugs Market Size Markets, 2021 & 2028
        4.1.2 Chemotherapy
        4.1.3 Immunotherapy
        4.1.4 Others
    4.2 By Type - Global Neuroblastoma Drugs Revenue & Forecasts
        4.2.1 By Type - Global Neuroblastoma Drugs Revenue, 2017-2022
        4.2.2 By Type - Global Neuroblastoma Drugs Revenue, 2023-2028
        4.2.3 By Type - Global Neuroblastoma Drugs Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Neuroblastoma Drugs Market Size, 2021 & 2028
        5.1.2 Hospitals
        5.1.3 Clinics
        5.1.4 Others
    5.2 By Application - Global Neuroblastoma Drugs Revenue & Forecasts
        5.2.1 By Application - Global Neuroblastoma Drugs Revenue, 2017-2022
        5.2.2 By Application - Global Neuroblastoma Drugs Revenue, 2023-2028
        5.2.3 By Application - Global Neuroblastoma Drugs Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Neuroblastoma Drugs Market Size, 2021 & 2028
    6.2 By Region - Global Neuroblastoma Drugs Revenue & Forecasts
        6.2.1 By Region - Global Neuroblastoma Drugs Revenue, 2017-2022
        6.2.2 By Region - Global Neuroblastoma Drugs Revenue, 2023-2028
        6.2.3 By Region - Global Neuroblastoma Drugs Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Neuroblastoma Drugs Revenue, 2017-2028
        6.3.2 US Neuroblastoma Drugs Market Size, 2017-2028
        6.3.3 Canada Neuroblastoma Drugs Market Size, 2017-2028
        6.3.4 Mexico Neuroblastoma Drugs Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Neuroblastoma Drugs Revenue, 2017-2028
        6.4.2 Germany Neuroblastoma Drugs Market Size, 2017-2028
        6.4.3 France Neuroblastoma Drugs Market Size, 2017-2028
        6.4.4 U.K. Neuroblastoma Drugs Market Size, 2017-2028
        6.4.5 Italy Neuroblastoma Drugs Market Size, 2017-2028
        6.4.6 Russia Neuroblastoma Drugs Market Size, 2017-2028
        6.4.7 Nordic Countries Neuroblastoma Drugs Market Size, 2017-2028
        6.4.8 Benelux Neuroblastoma Drugs Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Neuroblastoma Drugs Revenue, 2017-2028
        6.5.2 China Neuroblastoma Drugs Market Size, 2017-2028
        6.5.3 Japan Neuroblastoma Drugs Market Size, 2017-2028
        6.5.4 South Korea Neuroblastoma Drugs Market Size, 2017-2028
        6.5.5 Southeast Asia Neuroblastoma Drugs Market Size, 2017-2028
        6.5.6 India Neuroblastoma Drugs Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Neuroblastoma Drugs Revenue, 2017-2028
        6.6.2 Brazil Neuroblastoma Drugs Market Size, 2017-2028
        6.6.3 Argentina Neuroblastoma Drugs Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Neuroblastoma Drugs Revenue, 2017-2028
        6.7.2 Turkey Neuroblastoma Drugs Market Size, 2017-2028
        6.7.3 Israel Neuroblastoma Drugs Market Size, 2017-2028
        6.7.4 Saudi Arabia Neuroblastoma Drugs Market Size, 2017-2028
        6.7.5 UAE Neuroblastoma Drugs Market Size, 2017-2028
7 Players Profiles
    7.1 Pfizer
        7.1.1 Pfizer Corporate Summary
        7.1.2 Pfizer Business Overview
        7.1.3 Pfizer Neuroblastoma Drugs Major Product Offerings
        7.1.4 Pfizer Neuroblastoma Drugs Revenue in Global Market (2017-2022)
        7.1.5 Pfizer Key News
    7.2 Teva Pharmaceutical
        7.2.1 Teva Pharmaceutical Corporate Summary
        7.2.2 Teva Pharmaceutical Business Overview
        7.2.3 Teva Pharmaceutical Neuroblastoma Drugs Major Product Offerings
        7.2.4 Teva Pharmaceutical Neuroblastoma Drugs Revenue in Global Market (2017-2022)
        7.2.5 Teva Pharmaceutical Key News
    7.3 Johnson & Johnson
        7.3.1 Johnson & Johnson Corporate Summary
        7.3.2 Johnson & Johnson Business Overview
        7.3.3 Johnson & Johnson Neuroblastoma Drugs Major Product Offerings
        7.3.4 Johnson & Johnson Neuroblastoma Drugs Revenue in Global Market (2017-2022)
        7.3.5 Johnson & Johnson Key News
    7.4 Bristol-Myers Squibb
        7.4.1 Bristol-Myers Squibb Corporate Summary
        7.4.2 Bristol-Myers Squibb Business Overview
        7.4.3 Bristol-Myers Squibb Neuroblastoma Drugs Major Product Offerings
        7.4.4 Bristol-Myers Squibb Neuroblastoma Drugs Revenue in Global Market (2017-2022)
        7.4.5 Bristol-Myers Squibb Key News
    7.5 United Therapeutics
        7.5.1 United Therapeutics Corporate Summary
        7.5.2 United Therapeutics Business Overview
        7.5.3 United Therapeutics Neuroblastoma Drugs Major Product Offerings
        7.5.4 United Therapeutics Neuroblastoma Drugs Revenue in Global Market (2017-2022)
        7.5.5 United Therapeutics Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer
List of Tables
    Table 1. Neuroblastoma Drugs Market Opportunities & Trends in Global Market
    Table 2. Neuroblastoma Drugs Market Drivers in Global Market
    Table 3. Neuroblastoma Drugs Market Restraints in Global Market
    Table 4. Key Players of Neuroblastoma Drugs in Global Market
    Table 5. Top Neuroblastoma Drugs Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Neuroblastoma Drugs Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Neuroblastoma Drugs Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Neuroblastoma Drugs Product Type
    Table 9. List of Global Tier 1 Neuroblastoma Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Neuroblastoma Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Neuroblastoma Drugs Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Neuroblastoma Drugs Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Neuroblastoma Drugs Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Neuroblastoma Drugs Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Neuroblastoma Drugs Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Neuroblastoma Drugs Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Neuroblastoma Drugs Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Neuroblastoma Drugs Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Neuroblastoma Drugs Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Neuroblastoma Drugs Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Neuroblastoma Drugs Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Neuroblastoma Drugs Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Neuroblastoma Drugs Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Neuroblastoma Drugs Revenue, (US$, Mn), 2023-2028
    Table 30. Pfizer Corporate Summary
    Table 31. Pfizer Neuroblastoma Drugs Product Offerings
    Table 32. Pfizer Neuroblastoma Drugs Revenue (US$, Mn), (2017-2022)
    Table 33. Teva Pharmaceutical Corporate Summary
    Table 34. Teva Pharmaceutical Neuroblastoma Drugs Product Offerings
    Table 35. Teva Pharmaceutical Neuroblastoma Drugs Revenue (US$, Mn), (2017-2022)
    Table 36. Johnson & Johnson Corporate Summary
    Table 37. Johnson & Johnson Neuroblastoma Drugs Product Offerings
    Table 38. Johnson & Johnson Neuroblastoma Drugs Revenue (US$, Mn), (2017-2022)
    Table 39. Bristol-Myers Squibb Corporate Summary
    Table 40. Bristol-Myers Squibb Neuroblastoma Drugs Product Offerings
    Table 41. Bristol-Myers Squibb Neuroblastoma Drugs Revenue (US$, Mn), (2017-2022)
    Table 42. United Therapeutics Corporate Summary
    Table 43. United Therapeutics Neuroblastoma Drugs Product Offerings
    Table 44. United Therapeutics Neuroblastoma Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Neuroblastoma Drugs Segment by Type in 2021
    Figure 2. Neuroblastoma Drugs Segment by Application in 2021
    Figure 3. Global Neuroblastoma Drugs Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Neuroblastoma Drugs Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Neuroblastoma Drugs Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Neuroblastoma Drugs Revenue in 2021
    Figure 8. By Type - Global Neuroblastoma Drugs Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Neuroblastoma Drugs Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Neuroblastoma Drugs Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Neuroblastoma Drugs Revenue Market Share, 2017-2028
    Figure 12. US Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Neuroblastoma Drugs Revenue Market Share, 2017-2028
    Figure 16. Germany Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 17. France Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Neuroblastoma Drugs Revenue Market Share, 2017-2028
    Figure 24. China Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 28. India Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Neuroblastoma Drugs Revenue Market Share, 2017-2028
    Figure 30. Brazil Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Neuroblastoma Drugs Revenue Market Share, 2017-2028
    Figure 33. Turkey Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Neuroblastoma Drugs Revenue, (US$, Mn), 2017-2028
    Figure 37. Pfizer Neuroblastoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Teva Pharmaceutical Neuroblastoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Johnson & Johnson Neuroblastoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Bristol-Myers Squibb Neuroblastoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. United Therapeutics Neuroblastoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
62
Frequently Asked Questions
Neuroblastoma Drugs Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Neuroblastoma Drugs Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Neuroblastoma Drugs Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports